IPO Issue Details
Issue Price / Price Band₹610 per share (Fixed Price)
Face Value₹10 Per Share
Lot Size24 Shares per Lot
Total Issue Size93,38,288 shares (aggregating up to ₹569.64 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryFresh Capital-cum-Offer for Sale
Exchange / PlatformNSE & BSE
IPO TypeMainboard
Subscription OpenWed, 01 Sep 2021
Subscription CloseFri, 03 Sep 2021
Anchor AllotmentTue, 31 Aug 2021
Basis of AllotmentWed, 08 Sep 2021
Initiation of RefundsThu, 09 Sep 2021
Credit of Shares to DematMon, 13 Sep 2021
Listing DateTue, 14 Sep 2021
UPI Mandate Deadline2021-09-03
Application & Investment Details
Retail — Min (1 Lots)₹14,640 — 24 shares
Retail — Max (13 Lots)₹190,320 (13 Lots)
HNI — Min (14 Lots)₹2,04,960 — 336 shares
Pre-IPO Promoter Holding3,31,58,374 shares
Post-IPO Promoter Holding3,64,37,063 shares
Fresh Issue Shares32,78,688 shares (aggregating up to ₹200.00 Cr)
Offer for Sale Shares60,59,600 shares of ₹10 (aggregating up to ₹369.64 Cr)
About Ami Organics Ltd.
Incorporated in 2004, Ami Organics Limited is one of the leading research and development driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical ingredients (API) for New Chemical Entities, and material for agrochemicals and fine chemicals.The company has developed over 450 pharma intermediates across 17 key therapeutic areas i.e. anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant, and anti-coagulant. It supplies its products to more than 150 customers (including international customers) directly in India and in 25 countries overseas i.e. Europe, USA, China, Israel, Japan, Latin America, etc. Laurus Labs, Cadila Healthcare, Cipla Ltd are some of the domestic customers whereas Organike s.r.l.a. Socio Unico, Fermion Oly, Medichem S.A. and Midas Pharma GmbH are some of the international customers.The company has three manufacturing facilities in Gujarat situated at Sachin, Ankleshwar & Jhagadia, with an aggregate installed capacity of 6,060 MTPA.Competitive strengths:One of the leading manufacturers of certain Pharma Intermediates i.e. Dolutegravir, Trazodone, Entacapone, Nintedanib and Rivaroxaban.Strong and diversified product portfolio with 450+ Pharma Intermediates across 17 therapeutic areas.Extensive geographical presence and diversified customer base.Strong R&D, sales and marketing capabilitiesConsistent financial performance track record.
Objects of the Issue
Ami Organics Ltd. proposes to utilise the net proceeds from the Issue for the following objects:
1
1 Repayment/prepayment of certain financial facilities availed by the Company
140.00
2
2 Funding working capital requirements of the Company; and
90.00
3
3 General corporate purposes
45.98
Shareholding & Lock-in
Pre-IPO Promoter Holding
3,31,58,374 shares
Post-IPO Promoter Holding
3,64,37,063 shares
Lock-in Period (30%)October 8, 2021
Lock-in Period (50%)December 7, 2021